Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Operating Income (2020 - 2022)

Terns Pharmaceuticals filings provide 3 years of Operating Income readings, the most recent being -$16.8 million for Q4 2022.

  • Quarterly Operating Income fell 21.26% to -$16.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$62.0 million through Dec 2022, down 24.41% year-over-year, with the annual reading at -$20.1 million for FY2025, 80.29% up from the prior year.
  • Operating Income hit -$16.8 million in Q4 2022 for Terns Pharmaceuticals, up from -$17.3 million in the prior quarter.
  • Across five years, Operating Income topped out at -$8.7 million in Q3 2020 and bottomed at -$17.3 million in Q3 2022.
  • Average Operating Income over 3 years is -$12.4 million, with a median of -$12.6 million recorded in 2021.
  • The largest annual shift saw Operating Income crashed 58.28% in 2021 before it decreased 3.98% in 2022.
  • Terns Pharmaceuticals' Operating Income stood at -$8.8 million in 2020, then crashed by 58.28% to -$13.9 million in 2021, then fell by 21.26% to -$16.8 million in 2022.
  • Per Business Quant, the three most recent readings for TERN's Operating Income are -$16.8 million (Q4 2022), -$17.3 million (Q3 2022), and -$14.1 million (Q2 2022).